


Poolbeg Pharma plc – Annual Report, AGM Notice & Circular
27 May 2025 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the…

Heidelberg Pharma Announces First Patient Dosed in Phase I Study of Amanitin-based ADC Candidate HDP-102 for Non-Hodgkin Lymphoma
Ladenburg, Germany, 27 May 2025 – Heidelberg Pharma AG (FSE:…

Novo Nordisk Foundation enters into strategic framework agreement with the World Health Organization (WHO) to advance global health
With the agreement, the Foundation expands its existing collaboration…

Poolbeg Pharma plc – Proposed Retail Offer to raise up to £100,000
Poolbeg Pharma plc (AIM: POLB, 'Poolbeg Pharma' or the 'Company'),…

Poolbeg Pharma plc – Proposed Fundraising to raise approximately £4.1 million, Launch of Placing via accelerated bookbuild and Notice of General Meeting
Poolbeg Pharma plc (AIM: POLB, 'Poolbeg Pharma' or the 'Company'),…

Poolbeg Pharma plc – Results for the year ended 31 December 2024
20 May 2025- Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a…

Lars Rebien Sørensen to join the board of directors of Novo Nordisk A/S
Novo Nordisk A/S announced earlier today that Lars Rebien Sørensen,…

Novo Holdings appoints four new members to its Board of Directors further strengthening global perspectives and strategic capabilities
May 15, 2025 – Novo Holdings is pleased to announce the appointments…

Heidelberg Pharma to Present Promising New Clinical Data on its Lead ATAC Candidate HDP-101 at EHA 2025
HDP-101 demonstrated complete response in one female patient…

Kaerus Bioscience’s lead candidate KER-0193 granted Orphan Drug Designation and Rare Pediatric Drug Designation by U.S. FDA for treatment of Fragile X syndrome (FXS)
FDA’s two designations demonstrate KER-0193’s potential…

Resolution Therapeutics Announces Regenerative Macrophage Therapy (RMT) Manufacturing Process & Candidate Testing Suite at ASGCT 2025
– Proprietary manufacturing process enables robust and scalable…

Leucid Bio Announces Treatment of First Patient in AERIAL Trial of NKG2D CAR-T Therapy LEU011 for Solid Tumours
Initiation of AERIAL trial accelerated by successful first…

Vesper Bio achieves enrolment milestone in Phase Ib/IIa trial of lead candidate VES001 for frontotemporal dementia
Phase Ib/IIa trial is to evaluate the efficacy of VES001…

iOnctura commences randomized Phase I/II study in non-small cell lung cancer
First patient dosed in study investigating roginolisib + dostarlimab…

Alchemab Therapeutics signs landmark $415m licensing agreement for ATLX-1282 with Eli Lilly and Company
- New agreement with Lilly to license ATLX-1282, a first-in-class…

Astraveus Enters Strategic Partnership with NecstGen to evaluate Lakhesys Benchtop Cell FactoryTM for CAR-T therapy manufacturing
Agreement with Netherlands Center for the Clinical Advancement…

Domain Therapeutics Presents Novel Data Addressing Key Challenges in Oncology at AACR 2025
Phase I clinical results of DT-9081, an EP4 receptor antagonist,…

Novo Nordisk Foundation expands Challenge Programme outside of Denmark for the first time and significantly increases grants
Copenhagen, Denmark: The Novo Nordisk Foundation today announced…

Cycuria Therapeutics Launches with the Formation of a Distinguished Advisory Board and Significant Public Grant Funding
Cycuria aims to revolutionise treatment of hard-to-treat…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
We are specialists with an indepth understanding of how to communicate complex science to investors and corporate stakeholders. We help companies on their journey as they grow and have been trusted by hundreds of clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York